other material
confidence high
sentiment positive
materiality 0.75
Crinetics reports positive initial Phase 2 data for paltusotine in carcinoid syndrome; 65% symptom reduction
Crinetics Pharmaceuticals, Inc.
- 65% reduction in excess bowel movements and 65% reduction in flushing frequency in evaluable patients.
- No treatment-related severe or serious adverse events; most AEs mild-to-moderate (diarrhea, headache, abdominal pain).
- 87% (13/15) of completers enrolled in long-term extension; study enrollment complete (N=36).
- Topline results from full Phase 2 study expected in first half of 2024.